期刊
ONCOGENE
卷 37, 期 16, 页码 2137-2149出版社
SPRINGERNATURE
DOI: 10.1038/s41388-017-0116-9
关键词
-
资金
- Irish Cancer Society BREAST-PREDICT collaborative cancer research center [CCRGAL13]
- Irish Research Council (IRC) Postgraduate Scholarship [GOIPG/2016/978]
- IRC Enterprise Partnership Scheme Postdoctoral Research Fellowship [EPSPD/2016/20]
- Wellcome Trust biomedical vacation scholarship
- Health Research Board summer scholarship [SS-2015-1365]
- Science Foundation Ireland from the European Union's 7th Framework Programme [09/SRC/B1794, 12/RI/2338, HEALTH-2007-B-223298]
- charity Breast Cancer Research
- Health Research Board (HRB) [SS-2015-1365] Funding Source: Health Research Board (HRB)
- Irish Research Council (IRC) [EPSPD/2016/20, GOIPG/2016/978] Funding Source: Irish Research Council (IRC)
Adult Mesenchymal Stem Cells (MSCs) have a well-established tumor-homing capacity, highlighting potential as tumor-targeted delivery vehicles. MSCs secrete extracellular vesicle (EV)-encapsulated microRNAs, which play a role in intercellular communication. The aim of this study was to characterize a potential tumor suppressor microRNA, miR-379, and engineer MSCs to secrete EVs enriched with miR-379 for in vivo therapy of breast cancer. miR-379 expression was significantly reduced in lymph node metastases compared to primary tumor tissue from the same patients. A significant reduction in the rate of tumor formation and growth in vivo was observed in T47D breast cancer cells stably expressing miR-379. In more aggressive HER2-amplified HCC-1954 cells, HCC-379 and HCC-NTC tumor growth rate in vivo was similar, but increased tumor necrosis was observed in HCC-379 tumors. In response to elevated miR-379, COX-2 mRNA and protein was also significantly reduced in vitro and in vivo. MSCs were successfully engineered to secrete EVs enriched with miR-379, with the majority found to be of the appropriate size and morphology of exosomal EVs. Administration of MSC-379 or MSC-NTC cells, or EVs derived from either cell population, resulted in no adverse effects in vivo. While MSC-379 cells did not impact tumor growth, systemic administration of cell-free EVs enriched with miR-379 was demonstrated to have a therapeutic effect. The data presented support miR-379 as a potent tumor suppressor in breast cancer, mediated in part through regulation of COX-2. Exploiting the tumor-homing capacity of MSCs while engineering the cells to secrete EVs enriched with miR-379 holds exciting potential as an innovative therapy for metastatic breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据